Hannah Arem1, Mia Sorkin2, Brenda Cartmel2,3, Martha Fiellin2, Scott Capozza2, Maura Harrigan2, Elizabeth Ercolano2,3, Yang Zhou3, Tara Sanft3, Cary Gross3, Kathryn Schmitz4, Tuhina Neogi5, Dawn Hershman6, Jennifer Ligibel7, Melinda L Irwin8,9,10. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. 2. Yale School of Public Health, New Haven, CT, USA. 3. Yale Cancer Center, New Haven, CT, USA. 4. University of Pennsylvania, Philadelphia, PA, USA. 5. Boston University School of Medicine, Boston, MA, USA. 6. Columbia University, New York, NY, USA. 7. Dana Farber Cancer Institute, Boston, MA, USA. 8. Yale School of Public Health, New Haven, CT, USA. melinda.irwin@yale.edu. 9. Yale Cancer Center, New Haven, CT, USA. melinda.irwin@yale.edu. 10. Department of Chronic Disease Epidemiology, Yale School of Public Health, P.O. Box 208034, New Haven, CT, 06520-8034, USA. melinda.irwin@yale.edu.
Abstract
PURPOSE: Up to 50 % of postmenopausal breast cancer survivors taking aromatase inhibitors (AIs) experience AI-associated arthralgias, or joint pain, which causes many to stop taking AIs and may inhibit exercise, despite known health benefits. We thus evaluated exercise adherence and factors associated with better exercise adherence in breast cancer survivors experiencing AI-induced arthralgia in the (HOPE) year long randomized controlled trial. METHODS: We included 61 HOPE women randomized toexercise (150 min/week of moderate-intensity aerobic exercise and twice-weekly supervised strength training). Our main outcomes were aerobic exercise measured with daily activity logs, attendance at supervised exercise sessions, and changes in cardiorespiratory fitness, measured maximal oxygen consumption (VO2max). We examined means and standard deviations (SDs) for exercise adherence by demographic and medical characteristics and used the t test for mean differences. We also examined predictors of adherence using linear regression. RESULTS: On average, at the end of the year long trial, women reported 119 (SD 78) min/week of moderate-intensity aerobic exercise and participated in 70 % of supervised exercise training sessions. After adjustment for other factors that influence adherence, at 6 months postrandomization, only baseline VO2max was associated with higher aerobic exercise levels and at 12 months, only older age predicted better supervised exercise training attendance. CONCLUSIONS:Breast cancer survivors taking AIs and experiencing arthralgia are able to initiate and maintain a year long exercise program, regardless of other factors that influence activity levels. IMPLICATIONS FOR CANCER SURVIVORS: Breast cancer survivors can exercise at levels that have been shown to improve AI-associated arthralgia.
RCT Entities:
PURPOSE: Up to 50 % of postmenopausal breast cancer survivors taking aromatase inhibitors (AIs) experience AI-associated arthralgias, or joint pain, which causes many to stop taking AIs and may inhibit exercise, despite known health benefits. We thus evaluated exercise adherence and factors associated with better exercise adherence in breast cancer survivors experiencing AI-induced arthralgia in the (HOPE) year long randomized controlled trial. METHODS: We included 61 HOPE women randomized to exercise (150 min/week of moderate-intensity aerobic exercise and twice-weekly supervised strength training). Our main outcomes were aerobic exercise measured with daily activity logs, attendance at supervised exercise sessions, and changes in cardiorespiratory fitness, measured maximal oxygen consumption (VO2max). We examined means and standard deviations (SDs) for exercise adherence by demographic and medical characteristics and used the t test for mean differences. We also examined predictors of adherence using linear regression. RESULTS: On average, at the end of the year long trial, women reported 119 (SD 78) min/week of moderate-intensity aerobic exercise and participated in 70 % of supervised exercise training sessions. After adjustment for other factors that influence adherence, at 6 months postrandomization, only baseline VO2max was associated with higher aerobic exercise levels and at 12 months, only older age predicted better supervised exercise training attendance. CONCLUSIONS:Breast cancer survivors taking AIs and experiencing arthralgia are able to initiate and maintain a year long exercise program, regardless of other factors that influence activity levels. IMPLICATIONS FOR CANCER SURVIVORS: Breast cancer survivors can exercise at levels that have been shown to improve AI-associated arthralgia.
Entities:
Keywords:
Aromatase inhibitors; Arthralgia; Breast cancer; Exercise; Physical activity
Authors: William L Haskell; I-Min Lee; Russell R Pate; Kenneth E Powell; Steven N Blair; Barry A Franklin; Caroline A Macera; Gregory W Heath; Paul D Thompson; Adrian Bauman Journal: Circulation Date: 2007-08-01 Impact factor: 29.690
Authors: Cheryl L Rock; Colleen Doyle; Wendy Demark-Wahnefried; Jeffrey Meyerhardt; Kerry S Courneya; Anna L Schwartz; Elisa V Bandera; Kathryn K Hamilton; Barbara Grant; Marji McCullough; Tim Byers; Ted Gansler Journal: CA Cancer J Clin Date: 2012-04-26 Impact factor: 508.702
Authors: Caitlin C Murphy; L Kay Bartholomew; Melissa Y Carpentier; Shirley M Bluethmann; Sally W Vernon Journal: Breast Cancer Res Treat Date: 2012-06-12 Impact factor: 4.872
Authors: Dawn L Hershman; Theresa Shao; Lawrence H Kushi; Donna Buono; Wei Yann Tsai; Louis Fehrenbacher; Marilyn Kwan; Scarlett Lin Gomez; Alfred I Neugut Journal: Breast Cancer Res Treat Date: 2010-08-28 Impact factor: 4.872
Authors: R E Coleman; W W Bolten; M Lansdown; S Dale; C Jackisch; D Merkel; N Maass; P Hadji Journal: Cancer Treat Rev Date: 2007-12-21 Impact factor: 12.111
Authors: Rachel Ballard-Barbash; Christine M Friedenreich; Kerry S Courneya; Sameer M Siddiqi; Anne McTiernan; Catherine M Alfano Journal: J Natl Cancer Inst Date: 2012-05-08 Impact factor: 13.506
Authors: Christina M Dieli-Conwright; Frank C Sweeney; Kerry S Courneya; Debu Tripathy; Nathalie Sami; Kyuwan Lee; Thomas A Buchanan; Darcy Spicer; Leslie Bernstein; Joanne E Mortimer; Wendy Demark-Wahnefried Journal: Cancer Date: 2018-11-30 Impact factor: 6.860
Authors: Kelcey A Bland; Sarah E Neil-Sztramko; Amy A Kirkham; Alis Bonsignore; Cheri L Van Patten; Donald C McKenzie; Karen A Gelmon; Kristin L Campbell Journal: Support Care Cancer Date: 2018-04-13 Impact factor: 3.603
Authors: Vanessa B Sheppard; Chiranjeev Dash; Sarah Nomura; Arnethea L Sutton; Robert Lee Franco; Alexander Lucas; Masey Ross; Lucile Adams-Campbell Journal: Cancer Date: 2020-07-02 Impact factor: 6.860
Authors: Frank C Sweeney; Wendy Demark-Wahnefried; Kerry S Courneya; Nathalie Sami; Kyuwan Lee; Debu Tripathy; Kimiko Yamada; Thomas A Buchanan; Darcy V Spicer; Leslie Bernstein; Joanne E Mortimer; Christina M Dieli-Conwright Journal: Phys Ther Date: 2019-10-28
Authors: Tao Wang; Yu-Yan Huang; Xian-Liang Liu; Alex Molassiotis; Li-Qun Yao; Si-Lin Zheng; Jing-Yu Benjamin Tan; Hou-Qiang Huang Journal: Support Care Cancer Date: 2022-09-06 Impact factor: 3.359
Authors: Stephen J Carter; Gary R Hunter; Lyse A Norian; Bulent Turan; Laura Q Rogers Journal: Support Care Cancer Date: 2017-12-14 Impact factor: 3.603
Authors: Christina M Dieli-Conwright; Kerry S Courneya; Wendy Demark-Wahnefried; Nathalie Sami; Kyuwan Lee; Thomas A Buchanan; Darcy V Spicer; Debu Tripathy; Leslie Bernstein; Joanne E Mortimer Journal: J Clin Oncol Date: 2018-01-22 Impact factor: 44.544